Melodin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melodin

Property Description
Active ingredient Meloxicam (INN)
Form Tablets/capsules, solution for injection
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic, Oxicam derivative

What is the Active Ingredient in Melodin and What Type of Medicine is It?

The active ingredient in Melodin is Meloxicam, placing it in the major pharmacological class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).

Meloxicam is a synthetic compound, chemically defined as an Oxicam derivative, that is manufactured for systemic administration throughout the body. The specific structure of the agent classifies it among the enolic acid group of NSAIDs. As a single-ingredient pharmaceutical agent, its function relies entirely on the properties of Meloxicam, which is commonly supplied in oral forms, such as tablets, and injectable solutions. Meloxicam exhibits a longer half-life compared to several other NSAIDs, facilitating consistent therapeutic maintenance.

How Does the NSAID Class Relate to Melodin's General Purpose?

Melodin's core classification as an NSAID dictates its general purpose: providing symptomatic relief by counteracting inflammation, pain, and fever.

The active ingredient acts by intervening in the body's natural processes that generate inflammatory signals, specifically through the inhibition of prostaglandin synthesis. Meloxicam is generally characterized as a preferential Cyclooxygenase-2 (COX-2) inhibitor, an attribute that separates it from non-selective NSAIDs by focusing primarily on the enzyme induced at inflammation sites. The resulting effects are effective anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) actions, commonly used in situations requiring ongoing management of discomfort and swelling.

In Summary: The Foundational Definition of Melodin

Melodin is a synthetic, single-ingredient NSAID based on the active substance Meloxicam, providing a comprehensive anti-inflammatory response and symptomatic relief through targeted inhibition of inflammatory mediators.

What side effects are possible with Melodin?

Possible Side Effects and Safety Information

Melodin, which contains the active ingredient Meloxicam, has a defined safety profile reflecting its classification as an NSAID, with adverse reactions categorized by System-Organ Class and frequency in regulatory documents.

Official Adverse Reactions and Frequency

Adverse effects are documented across multiple body systems. Gastrointestinal (GI) and Nervous System effects are frequently reported.

Frequency Classification Sample Adverse Reactions (Official Documentation)
Most Common (ge 5%) Diarrhea, dyspepsia (indigestion), upper respiratory tract infection.
Common (1% to 10%) Nausea, vomiting, abdominal pain, headache, dizziness, hypertension, edema.
Uncommon (ge 0.1% to <1%) Gastritis, somnolence, anemia, flushing.

Serious Safety Constraints

Official labeling mandates highlight for potential life-threatening risks associated with the NSAID class, which can occur at any time during treatment:

  • Cardiovascular Thrombotic Events: The risk of serious events, including myocardial infarction (heart attack) and stroke, which can be fatal, may increase with the duration of use.
  • Gastrointestinal Toxicity: Serious complications include bleeding, ulceration, and perforation of the stomach or intestines.
  • Hypersensitivity: Severe skin reactions, such as Stevens-Johnson syndrome (SJS), have been reported, with the highest risk often occurring early in therapy.

Population-Specific Safety Notes

Regulatory documents include specific notes for certain groups. Older adults are at a greater risk for serious GI events. The medicine is contraindicated in the third trimester of pregnancy (starting at 30 weeks gestation) due to the risk of fetal harm. Use is restricted in individuals with severe heart failure or immediately following coronary artery bypass graft (CABG) surgery.

Overdose and Emergency Response

Official regulatory documentation describes Melodin (Meloxicam) overdose as potentially presenting with a range of initial symptoms, including common signs such as Nausea, Vomiting, Epigastric pain, Lethargy, and Drowsiness. The overdose profile emphasizes the risk of Severe Systemic Outcomes affecting multiple physiological systems. These life-threatening manifestations include Gastrointestinal bleeding, Acute renal failure, Convulsions, Respiratory depression, and Cardiovascular collapse, which may progress to Cardiac arrest and Coma.

Immediate medical attention must be sought when an overdose is suspected or upon the manifestation of any severe clinical signs. Regulatory guidance confirms that no specific antidote is known for this medication. Therefore, management is mandated to be symptomatic and supportive treatment.

Procedural interventions described in official labeling may include techniques like gastric lavage and the administration of activated charcoal to reduce drug absorption, alongside other supportive measures. Individuals with pre-existing heart conditions or a history of gastrointestinal issues, as well as the elderly, are specifically noted to have an increased risk for severe events.

Therapeutic Uses of Melodin

Melodin is commonly used in conditions presenting with systemic or localized discomfort.

Therapeutic Support for Chronic Symptom Domains

Melodin is applied in conditions marked by heightened, long-term symptoms such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). It is used to address pronounced symptoms of joint swelling, tenderness, and stiffness that interferes with daily functioning that accompany these chronic inflammatory joint diseases. Providing symptomatic relief may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases. It is also commonly used to help with the symptomatic management of Juvenile Idiopathic Arthritis (JIA) in appropriate patient groups.

“Melodin is relevant for easing symptoms that interfere with daily comfort.”

Addressing Symptoms Associated with Acute Episodes

The medication is relevant in clinical settings that involve acute or unstable symptom patterns. This includes situations where symptomatic assistance is needed for acute episodes, such as intense gouty arthritis flares, or the management of acute musculoskeletal pain and postoperative discomfort where inflammation causes significant functional strain. Applied during phases of increased distress or discomfort, Melodin is relevant for easing symptoms that may assist with maintaining functional stability when symptoms become more noticeable.

Quick Fact: Relief for Inflammatory Discomfort
Offers supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. DailyMed (NIH) Meloxicam Label

Eligibility and Restrictions for Use

Official Population Eligibility for Melodin (Meloxicam)

Official regulatory documents define specific populations who are permitted to use Melodin, as well as those for whom use is contraindicated or restricted.

Contraindicated Populations (Must Not Use)
Patients with known hypersensitivity to meloxicam, aspirin, or other NSAIDs (due to risk of allergic-type reactions).
Individuals in the setting of coronary artery bypass graft (CABG) surgery.
Patients with active gastrointestinal ulceration, bleeding, or severe non-dialyzed renal impairment.
Women at 30 weeks gestation and later (third trimester of pregnancy).
Restricted or Conditional Use
Pediatrics: Approved only for Juvenile Idiopathic Arthritis (JIA) in patients 2 years of age and older. Use in children under 2 years is not established.
Older Adults: Generally approved, but may be at greater risk for serious GI or renal effects.
Organ Function: Use is not recommended in severe renal impairment and should be used with caution in mild-to-moderate renal or hepatic impairment.
Pregnancy/Lactation: Use should be avoided from 20 weeks gestation onward; not recommended while breastfeeding due to lack of data.

This eligibility structure is mandated by government authorities to ensure that use is strictly confined to patients without high-risk pre-existing conditions or physiological states where the drug's use is prohibited.

What should I know about interactions with other medicines?

Melodin (Melatonin), when used as an authorised medicinal product, is primarily metabolised by the hepatic cytochrome P450 enzymes, particularly CYP1A2. This metabolic pathway is the basis for several documented drug-drug interactions where the concentration of Melodin in the blood may be significantly altered.

Drug and Substance Interactions

Interacting Substance Category Specific Examples Nature of Interaction
CYP1A2 Inhibitors Fluvoxamine, Quinolones (e.g., Ciprofloxacin), Cimetidine, Oestrogens (e.g., Hormone Replacement Therapy/Contraceptives) Significantly increased Melodin plasma concentration due to inhibited metabolism. This combination is generally advised to be avoided for Fluvoxamine.
CYP1A2 Inducers Carbamazepine, Rifampicin, Cigarette Smoking Reduced Melodin plasma concentrations due to increased metabolism, potentially reducing its effectiveness.
Sedative/Hypnotic Agents Benzodiazepines (e.g., Midazolam, Temazepam), Non-Benzodiazepine Hypnotics (e.g., Zolpidem, Zaleplon, Zopiclone) Enhanced sedative effect. Concomitant use with Zolpidem, for example, has shown increased impairment of attention, memory, and coordination.
Anticoagulants Warfarin, other Vitamin K Antagonists Potential to affect the anticoagulation activity, possibly requiring dose adjustment of the anticoagulant. This combination should be avoided or used with caution and monitored closely.
Antihypertensive Agents Nifedipine (Calcium Channel Blocker) Melodin may potentially reduce the blood pressure-lowering effect. Caution and dose adjustment may be necessary.

Other Interaction Constraints

  • Alcohol: Alcohol should not be consumed concurrently as it can diminish the effect of Melodin on sleep.
  • Food/Timing: Limited data suggests that taking Melodin close to a carbohydrate-rich meal may impair blood glucose control for several hours in individuals with significantly impaired glucose tolerance or diabetes. Some product information suggests spacing Melodin intake at least 2 hours before or after a meal.

The primary interaction concern is the potential for significant changes in Melodin's concentration when combined with medicines that affect the CYP1A2 enzyme. The second major area of interaction involves enhanced central nervous system (CNS) depression when combined with other sedating medicines.

Mechanism of Action

alpha. Regulation of Cellular Energy Metabolism

This domain describes the molecule's action as a competitive inhibitor of the BBOX enzyme (gamma-Butyrobetaine Hydroxylase) and the OCTN2 transporter. This dual interaction restricts the final synthesis step of L-carnitine and its transport into cells. By reducing cellular L-carnitine availability, the mechanism restricts the ability of the cell to facilitate the import and oxidation of long-chain fatty acids for energy, resulting in the redirection of cellular substrate preference.

beta. Establishment of Oxygen Efficiency

The restriction of fatty acid oxidation compels a greater reliance on glucose oxidation (glycolysis) as the primary source of cellular ATP. This shift is relevant for cellular physiology because glucose metabolism requires less oxygen to generate the same amount of ATP, which establishes a metabolic state requiring a lower rate of oxygen consumption for energy synthesis.

gamma. Limitation of Acylcarnitine Accumulation

The inhibition of fatty acid oxidation prevents the full execution of the beta-oxidation process. This mechanism modulates the rate of acylcarnitine formation, influencing cellular concentrations of these intermediates. This influence on intermediate concentrations affects the maintenance of cellular function in metabolically active tissues.

Dosage and Administration Information

How to Use Melodin: Administration Guidelines

Melodin, which contains the active substance Meloxicam, is administered according to a protocol focused on providing symptomatic relief using the lowest effective dose for the shortest period. The total dosage, regardless of the administration route, must adhere to a strict 15 mg daily maximum for adult patients.


Dosage and Frequency Principles

The medication is used for once-daily administration, consistent with its long duration of action. The standard adult dose ranges from 7.5 mg to 15 mg, which may be taken as tablets, capsules, or an oral suspension. Oral forms may be taken with water, during a meal, or after a meal.


Administration Routes and Duration

Melodin is available for both oral and injectable (Intravenous or Intramuscular) administration. The injectable form, which may be supplied in a 15 mg/1.5 mL solution, is designated for short-term management, such as the initiation of treatment or during acute episodes. Treatment protocols involve transitioning from the injectable form to the oral form after no more than 3 to 5 days. The oral form is the established route for long-term maintenance.


Specific Population Rules

Administration adjustments are utilized for specific groups. For older adults, the starting and maintenance dose is typically limited to 7.5 mg daily. Pediatric dosing for conditions like Juvenile Idiopathic Arthritis is weight-based (e.g., 0.125 mg/kg), with a maximum daily dose of 7.5 mg, and the oral suspension is generally preferred for children.


Key Administration Constraint Detail
Maximum Daily Dose 15 mg (Oral and Injectable combined)
Frequency Once Daily (QD)
Missed Dose Take the next dose at the regular time; do not double the dose

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Studies

Research has explored whether the study drug was evaluated for its potential role in managing symptoms of severe, chronic inflammatory conditions. Trials examined the drug’s potential effect on key disease indicators, including C-reactive protein (CRP) levels and overall patient-reported pain scores.

  • Study Population: The trials primarily included adult participants who had not responded adequately to traditional first-line treatments (e.g., NSAIDs, standard disease-modifying agents).

Key Findings from Randomized Controlled Trials (RCTs)

A series of placebo-controlled RCTs, primarily conducted over 12 and 24 weeks, evaluated whether there was an increase in joint mobility and a change in swelling in the treatment group compared to the control group.

  • Symptom Change: The aggregated data from these trials reported a difference in average daily pain scores between the study group and the placebo group. The trials used a 10-point Visual Analog Scale (VAS) to measure pain.
  • Physical Function: Secondary analyses examined whether there was an influence on participants’ ability to perform daily activities, as measured by a validated function assessment score.

Combination Therapy Research

A combination study examined whether the drug, when used with standard physical therapy, resulted in different long-term outcomes compared to physical therapy alone. This study followed participants for a period of one year.

  • Long-Term Outcomes: The study reported a larger percentage of participants in the combination therapy group meeting a pre-defined measurement point after 12 months.
  • Administration Influence: Studies have investigated whether the timing of administration in relation to food intake influenced pain levels or absorption rates.

Safety and Side Effects Data

Research evaluated whether the drug was associated with a change in the frequency and intensity of flare-ups. The most commonly identified adverse events in clinical trials were:

  • Gastrointestinal distress (e.g., nausea, mild diarrhea).
  • Headache.
  • Drowsiness: Studies noted drowsiness as an adverse event.

Further long-term observational studies are investigating the potential for rare, serious adverse events.

Frequently Asked Questions (FAQ)

Common questions about Melodin (FAQ)


Q: Does Melodin cause any change in sleep patterns or mood?

A: Drowsiness (somnolence), dizziness, and difficulty sleeping (insomnia) are listed as reported side effects in official documents. Changes in mood, such as depression or nervousness, have also been reported in association with the drug. Official guidance emphasizes communication with a health professional regarding any changes in sleep or mood.


Q: Is it okay to drive or operate machinery after taking Melodin?

A: Official product information states that Melodin may cause side effects like dizziness, drowsiness, or blurred vision. Caution is necessary, and operation of machinery or vehicles is not advised if these symptoms occur.


Q: How long does it typically take before I might notice Melodin working?

A: How quickly Melodin works depends on the specific formulation and the condition being treated. For chronic conditions, the full benefits may not be fully noticeable for several days of consistent use. While the injectable form may have a quicker onset, the oral tablet typically reaches its peak concentration hours after a dose.


Q: Is Melodin known to be addictive or habit-forming?

A: According to regulatory classification, Melodin (Meloxicam) is a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is not classified as a controlled substance and is not generally considered to be addictive or habit-forming.


Q: Can Melodin be taken with common over-the-counter pain relievers?

A: Official regulatory documents generally advise against taking Melodin at the same time as other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This includes common over-the-counter NSAIDs like aspirin or ibuprofen, as combining them may significantly increase the risk of serious gastrointestinal side effects.


Q: Does Melodin interact with specific types of foods or drinks?

A: Official documents state that alcohol consumption should be avoided when using Melodin because it may increase the risk of gastrointestinal bleeding. While the medication can be taken with or after food, some product information suggests avoiding carbohydrate-rich meals within two hours of taking the dose.


Q: Is it necessary to have routine blood tests while using Melodin?

A: Official safety information indicates that routine monitoring may be necessary for some patients, particularly those taking Melodin long-term or those with pre-existing conditions. This monitoring may include checks of your kidney function, liver function, and blood count.


Q: Are there any long-term effects associated with taking Melodin?

A: Melodin is often used for the long-term maintenance of chronic conditions. Regulatory warnings indicate that the risk of serious cardiovascular events, such as heart attack or stroke, and serious gastrointestinal complications, like bleeding or ulceration, may increase with the length of use.


Q: Is Melodin safe for elderly patients to use?

A: Use in older patients is generally permitted. However, official regulatory warnings highlight that this population is at a greater risk for serious gastrointestinal and kidney-related adverse events. Caution is generally observed for this population due to the reported risks.


Q: If a person feels better, can they stop taking Melodin immediately?

A: Official guidance indicates that treatment discontinuation is a decision to be made in consultation with a healthcare provider. Because the medication is used to manage the symptoms of chronic inflammatory conditions, stopping immediately may result in the return or worsening of pain and inflammation.


Q: Can Melodin affect fertility or be used during pregnancy?

A: Regulatory documents note that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may cause temporary infertility in women. Its use is advised against from 20 weeks of gestation and is strictly prohibited in the third trimester (30 weeks onward) due to the risk of harm to the fetus’s heart and kidneys.


Q: Is there a generic version of Melodin available?

A: Official regulatory approval records confirm that Melodin (Meloxicam) is available as a widely used generic medication, in addition to various brand-name products.


Q: What happens if a person accidentally takes too much Melodin?

A: Taking too much Melodin can result in serious symptoms such as lethargy, nausea, vomiting, and stomach pain. More severe complications, including internal bleeding or cardiovascular collapse, are possible. In the event of an accidental overdose, seeking emergency medical attention is the official recommended course of action.


Q: Is it true that Melodin can interact with herbal supplements?

A: Regulatory documents emphasize the importance of discussing all medications with your healthcare provider due to potential interactions. Official guidance stresses informing a provider about all supplements, vitamins, and herbal products, due to potential interactions.


Q: Does Melodin affect concentration or memory?

A: Common side effects like dizziness and somnolence (drowsiness) are reported in official documents. These Central Nervous System (CNS) effects may temporarily impair cognitive functions such as concentration and memory.


Q: Are there any differences in how Melodin works in children compared to adults?

A: The drug’s mechanism of action, which involves reducing inflammation by inhibiting prostaglandin synthesis, is understood to be the same in children and adults. Official information primarily notes differences in administration, such as the use of weight-based dosing for children with Juvenile Idiopathic Arthritis (JIA).


Q: Where can I find the official regulatory information about Melodin?

A: Official, authoritative information can be accessed through the Patient Information Leaflet (PIL) or Medication Guide that comes with the medicine. Full prescribing details are also available from national regulatory bodies like the FDA and EMA.


Q: Can using Melodin lead to withdrawal symptoms if stopped?

A: Official information does not associate Melodin with the classic withdrawal symptoms seen with controlled substances. However, if the medication is stopped, the underlying pain and inflammation the drug was treating may return or intensify.


Q: Is Melodin known to cause weight gain or weight loss?

A: Regulatory documents list fluid retention and edema (swelling) as common adverse reactions, which may result in an unexplained or sudden gain in weight. Melodin is not directly linked to weight loss or changes in body fat.


Q: What is the shelf life of Melodin, and how should it be stored generally?

A: The precise shelf life is printed on the medication's packaging and expiration date. Regulatory standards require that Melodin be generally stored at controlled room temperature, protected from moisture and light, and kept in its original, tightly closed container.


Q: Does Melodin have a 'Black Box Warning' or similar alert?

A: Yes, official U.S. regulatory information confirms that Melodin (Meloxicam) carries a Boxed Warning. This alert highlights the risk of potentially life-threatening cardiovascular thrombotic events (like heart attack and stroke) and serious gastrointestinal events (like bleeding, ulceration, and perforation).


Q: What should a patient do if they feel a severe side effect?

A: According to official patient guidelines, if you experience signs of a severe adverse event—such as sudden chest pain, shortness of breath, sudden weakness, or bloody/black stools—the official guidance is to stop the medication and seek emergency medical attention.


Q: Do other medications need to be stopped before starting Melodin?

A: Official interaction data emphasizes the importance of discussing all current medications with a healthcare provider before starting Melodin. Drugs with known significant interactions, such as certain blood thinners or CYP1A2 inhibitors, may need to be adjusted or stopped before use.


Q: Can Melodin be crushed or split?

A: Regulatory instructions state that Melodin tablets should be swallowed whole. Unless a specific formulation is designed for modification, standard tablets are generally advised to be swallowed whole.


Q: Is Melodin considered a controlled substance?

A: Melodin (Meloxicam) is not categorized as a scheduled or federally controlled substance by drug regulatory agencies.


Q: Can Melodin make existing mental health conditions worse?

A: Official adverse event reporting includes Central Nervous System (CNS) side effects such as depression, nervousness, and drowsiness. Official guidelines recommend that patients with existing mental health conditions be monitored for changes in symptoms during therapy.


Q: Are there specific instructions for what to do before a planned surgery while taking Melodin?

A: Official safety documents highlight the need to inform the surgical team about taking Melodin before any planned procedure, as the drug can affect blood clotting. It is strictly prohibited for use immediately following coronary artery bypass graft (CABG) surgery.


Q: Can I take Melodin if I have a history of liver or kidney problems?

A: Regulatory guidance advises that use is not recommended in cases of severe active liver or kidney impairment. Official guidance suggests that cautious use and close monitoring by a health professional are necessary for individuals with mild impairment or a history of these problems.


Q: Is it common to experience headache when starting Melodin?

A: Headache is listed as a common adverse reaction, meaning it occurred in 1% to 10% of patients during clinical trials. However, official data does not specify whether this side effect is statistically more common in the initial days or weeks of starting treatment.


Q: How long after starting Melodin does its full effect usually appear?

A: For chronic conditions like arthritis, Melodin has a known delayed time to onset compared to some other pain relievers. Studies indicate that several days of consistent therapy are typically required to achieve the medication’s full anti-inflammatory and pain-relieving effects.


Q: Are there specific times of day that Melodin is generally recommended to be taken?

A: The drug is prescribed for once-daily administration. While the specific time is often flexible based on the patient’s routine and symptom relief needs, it may be taken with or without food as guided by the prescribing instructions.


Q: Is Melodin effective for short-term or only for long-term use?

A: Official administration guidelines state that the injectable form is specifically limited to short-term management. The oral forms are approved for the long-term maintenance of chronic conditions like arthritis but may also be used for shorter periods as needed for symptoms.


Q: What is the typical timeframe for someone to be on Melodin therapy?

A: The injectable form is strictly limited to a maximum of 3 to 5 days of treatment. For chronic conditions, oral therapy is intended for long-term maintenance, which, according to regulatory standards, can extend over many months or years depending on the patient's condition and the evaluation of a health professional.


Q: What is the official approved indication for Melodin?

A: According to official regulatory documents, Melodin is approved to provide relief from the signs and symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years and older.

How should Melodin be stored and disposed of?

Storage and Disposal Information

The storage and disposal instructions for Melodin are based on the regulatory requirements for its active ingredient, Meloxicam.

Storage Conditions

  • Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C (86 F).
  • The medication must be kept in a dry place and protected from moisture and light.
  • The oral suspension form must be kept from freezing.
  • Tablets must be dispensed in a tight container, and all containers must be kept tightly closed.

Safety and Disposal

  • Keep this and all medicines out of the sight and reach of children.
  • Dispose of unused or expired Melodin according to local requirements; consult a pharmacist or healthcare provider for guidance.
  • Melodin is not on the list of medicines recommended for disposal by flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melodin found in:

A-Z Index: